© 1995 American Heart Association, Inc.
Articles |
Ribozyme-Mediated Inhibition of Expression of Leukocyte-type 12-Lipoxygenase in Porcine Aortic Vascular Smooth Muscle Cells
From the Department of Diabetes, Endocrinology, and Metabolism, City of Hope Medical Center, and Center for Molecular Biology and Gene Therapy (J.R.), Loma Linda (Calif) University, School of Medicine.
Correspondence to Jerry L. Nadler, MD, Department of Diabetes, Endocrinology, and Metabolism, City of Hope Medical Center, 1500 E Duarte Rd, Duarte, CA 91010.
Abstract Activation of a leukocyte-type 12-lipoxygenase (12-LO) has been proposed to be an important mechanism for angiotensin II– and glucose-induced vascular smooth muscle cell growth. Currently, no specific pharmacological inhibitors for the leukocyte-type 12-LO are available to test this hypothesis. We have therefore designed a chimeric DNA-RNA hammerhead ribozyme to produce cleavage at the first GUC sequence at nucleotide 7 of porcine leukocyte 12-LO mRNA. The ribozyme was tested in vitro with a 206-base 12-LO mRNA as substrate. We observed that the ribozyme specifically and dose-dependently cleaved porcine leukocyte 12-LO mRNA at the predicted site under physiological temperature. Furthermore, we also efficiently delivered the ribozyme into porcine aortic vascular smooth muscle cells by transfection with cationic liposomes. The ribozyme caused a dose-dependent decrease in levels of porcine leukocyte-type 12-LO mRNA in these cells and was more potent than an antisense oligonucleotide directed against porcine leukocyte 12-LO. The 12-LO ribozyme also attenuated 12-LO protein levels in the cells. The action of the ribozyme was primarily a result of its catalytic activity, since a modified ribozyme that lacks catalytic activity showed reduced effects. This represents the first ribozyme directed against a mammalian LO pathway. These results demonstrate the potential utility of new ribozyme technology to generate novel agents for gene modulation experiments to modify the development or progression of vascular disease in humans.
Key Words: lipoxygenase • ribozyme • vascular smooth muscle • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  J. Huber, A. Furnkranz, V. N. Bochkov, M. K. Patricia, H. Lee, C. C. Hedrick, J. A. Berliner, B. R. Binder, and N. Leitinger Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase J. Lipid Res., May 1, 2006; 47(5): 1054 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Srinivasan, M. E. Hatley, K. B. Reilly, E. C. Danziger, and C. C. Hedrick Modulation of PPAR{alpha} Expression and Inflammatory Interleukin-6 Production by Chronic Glucose Increases Monocyte/Endothelial Adhesion Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 851 - 857. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Reddy, S. G. Adler, Y.-S. Kim, L. Lanting, J. Rossi, S.-W. Kang, J. L. Nadler, A. Shahed, and R. Natarajan Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells Am J Physiol Renal Physiol, November 1, 2002; 283(5): F985 - F994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wang, M. Liu, B. Mullah, D. P. Siderovski, and R. R. Neubig Receptor-selective Effects of Endogenous RGS3 and RGS5 to Regulate Mitogen-activated Protein Kinase Activation in Rat Vascular Smooth Muscle Cells J. Biol. Chem., July 5, 2002; 277(28): 24949 - 24958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Gu, H. Pei, L. Thomas, J. L. Nadler, J. J. Rossi, L. Lanting, and R. Natarajan Ribozyme-Mediated Inhibition of Rat Leukocyte-Type 12-Lipoxygenase Prevents Intimal Hyperplasia in Balloon-Injured Rat Carotid Arteries Circulation, March 13, 2001; 103(10): 1446 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Amarzguioui, G. Brede, E. Babaie, M. Grotli, B. Sproat, and H. Prydz Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes Nucleic Acids Res., November 1, 2000; 28(21): 4113 - 4124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Wang, M. Enjoji, M. Tiebel, S. Ochsner, L. Chan, and B.-B. Teng Hammerhead Ribozyme Cleavage of Apolipoprotein B mRNA Generates a Truncated Protein J. Biol. Chem., August 20, 1999; 274(34): 24161 - 24170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Nakaar, B. U. Samuel, E. O. Ngo, and K. A. Joiner Targeted Reduction of Nucleoside Triphosphate Hydrolase by Antisense RNA Inhibits Toxoplasma gondii Proliferation J. Biol. Chem., February 19, 1999; 274(8): 5083 - 5087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Frimerman, P. J. Welch, X. Jin, N. Eigler, S. Yei, J. Forrester, H. Honda, R. Makkar, J. Barber, and F. Litvack Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model Circulation, February 9, 1999; 99(5): 697 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Natarajan, H. Pei, J.-L. Gu, J. M. Sarma, and J. Nadler Evidence for 12-lipoxygenase induction in the vessel wall following balloon injury Cardiovasc Res, February 1, 1999; 41(2): 489 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, B. Mullah, C. Hansen, J. Asundi, and J. D. Robishaw Ribozyme-mediated Suppression of the G Protein gamma 7 Subunit Suggests a Role in Hormone Regulation of Adenylylcyclase Activity J. Biol. Chem., October 10, 1997; 272(41): 26040 - 26048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Natarajan, J. Rosdahl, N. Gonzales, and W. Bai Regulation of 12-Lipoxygenase by Cytokines in Vascular Smooth Muscle Cells Hypertension, October 1, 1997; 30(4): 873 - 879. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. K. Patricia, R. Natarajan, A. N. Dooley, F. Hernandez, J.-L. Gu, J. A. Berliner, J. J. Rossi, J. L. Nadler, R. S. Meidell, and C. C. Hedrick Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells Circ. Res., April 13, 2001; 88(7): 659 - 665. [Abstract] [Full Text] [PDF]
|
|